Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Commentary

Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity

Edward Uchio, Frank L. Meyskens and Ping H. Wang
Edward Uchio
Department of Urology, University of California, Irvine, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank L. Meyskens
Chao Family Comprehensive Cancer Center, University of California, Irvine, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ping H. Wang
UC Irvine Diabetes Center, University of California, Irvine, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: phwang@uci.edu
DOI: 10.1158/1940-6207.CAPR-16-0173 Published October 2016
  • Article
  • Info & Metrics
  • PDF
Loading

See related article by Wang et al., p. 779

Prostate cancer still remains the most common malignancy in American men. In this issue, Wang and colleagues studied the effect of metformin on prostate cancer incidence in the Veterans Administration Health Care System (1). According to their analyses, metformin had a protective effect on prostate cancer risk in the Hispanic Americans but not in non-Hispanic White Americans, African Americans, or Asian Americans. The scope of prostate cancer apparently varies by race, with African American men reported to have a higher incidence, more advanced anatomic stage at the time of diagnosis, and higher cancer-specific mortality. Potential biological explanations for these disparities include racial differences in tumor biology and responsiveness to treatment; potential extrinsic explanations include differences in access to care, patterns of screening, and treatments received. However, when these men of varying race were cared for in an equal-access health care system, differential outcomes most likely reflected variations in underlying biological factors.

Metformin has been widely used as a first-line therapy for type I diabetes, but its exact mechanism is not completely understood. The pharmaceutical effects of metformin are mediated through the AMP-activated protein kinase (AMPK) signaling, as well as AMPK-independent pathways (2). AMPK plays a key role in sensing and regulating ATP–AMP homeostasis. AMPK increases ATP production through fatty acid and glucose metabolism, promotes catabolism, and attenuates oxidative stress and inflammation. Dysfunction of AMPK signaling has been implicated in the development of cancers, but there were conflicting opinions regarding the roles of AMPK signaling in cancer cells (3, 4). The positive action of AMPK signaling on cell growth and its antioxidative stress effect suggested a tumor-promoting effect, whereas the tumor suppressor LKB1 could phosphorylate AMPK-α subunit, and loss of LKB1/APMK signaling might aggravate tumor progression (3, 4). This makes AMPK seem like the two-faced Roman god Janus in cancer biology. There is evidence that metformin has AMPK-independent pharmacologic actions. Metformin may modulate mitochondria oxidative phosphorylation, oxidative stress, and inflammation in the absence of AMPK. However, it is not entirely clear how AMPK-independent actions of metformin regulate cancer biology.

Glycerin-N-methyltransferase (GNMT) is expressed at high levels in prostate and pancreas. GNMT plays a critical role in the development of prostate cancer by catalyzing transfer of methyl group to DNA and histones that eventually transforms neoplastic gene programming (5). Metformin suppressed DNA methylation in pancreatic islet cells (6). Although whether the anticancer effect of metformin in prostate involves this mechanism is not known, GNMT genotyping data raised the possibility that the impact of genetic variations can be divergent in different races. In European Americans, GNMT rs1094859 allele variations were associated with increased risk for nonaggressive prostate cancer but not aggressive cancer (7). However, the same allele was not associated with nonaggressive prostate cancer risk and had a protective association against aggressive prostate cancer in Taiwanese men (8). For diabetes control, there is also evidence that the efficacy of metformin for glycemic control is not uniform across different ethnic groups. For example, African Americans appeared to be more responsive to metformin than Caucasians (9). Further study is needed to analyze the effect of metformin on prostate cancer risk in the context of genetic polymorphism across different ethnicities.

The effect of metformin on cancer risk and prognosis has not been consistent in previous studies (10). The anticancer action of metformin may vary under different genetic backgrounds, antineoplastic drugs, and metabolic status. Metformin can modulate hyperinsulinemia and insulin resistance, which had been linked to higher prostate cancer risk (11), but the status of hyperinsulinemia was rarely investigated in the context of metformin and prostate cancer in epidemiology studies. Mitochondria is a target of metformin actions, and mitochondria-mediated apoptosis plays a key role in prostate cancer response to nonsurgical treatments. Diverse mitochondrial DNA haplogroups have been recognized in different female inheritance lineages through human evolution and dates back to the human ancestors in Africa and subsequent migration around the world (12). Each ethnic group and subgroup retains unique mitochondria genetic signatures. Specific haplogroups had been associated with human cancer and metabolic diseases (12, 13). It will be interesting to analyze whether differential effects of metformin on prostate cancer in different ethnicity can be explained by mitochondria genetics or the genetics of nuclear genes that modulate mitochondria function.

Metformin is one of the most prescribed medications in the United States, and prostate cancer is the most common male malignancy. To clarify the effect of metformin on prostate cancer in future studies, there is a need to better integrate race-specific genetics and metabolic profile in a mechanistic carcinogenesis model with cancer incidence and survival.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: E. Uchio, F.L. Meyskens, P.H. Wang

Development of methodology: E. Uchio, P.H. Wang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E. Uchio

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E. Uchio

Writing, review, and/or revision of the manuscript: E. Uchio, F.L. Meyskens, P.H. Wang

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E. Uchio, P.H. Wang

Study supervision: E. Uchio, F.L. Meyskens, P.H. Wang

  • Received July 1, 2016.
  • Accepted July 6, 2016.
  • ©2016 American Association for Cancer Research.

References

  1. 1.↵
    1. Wang C-P,
    2. Lehman DM,
    3. Lam YWF,
    4. Kuhn JG,
    5. Mahalingam D,
    6. Weitman S,
    7. et al.
    Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes. Cancer Prev Res 2016;9:779–87.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Pernicova I,
    2. Korbonits M
    . Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143–56.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Lin R,
    2. Elf S,
    3. Shan C,
    4. Kang HB,
    5. Ji Q,
    6. Zhou L,
    7. et al.
    6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol 2015;17:1484–96.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Monteverde T,
    2. Muthalagu N,
    3. Port J,
    4. Murphy DJ
    . Evidence of cancer-promoting roles for AMPK and related kinases. FEBS J 2015;282:4658–71.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Song YH,
    2. Shiota M,
    3. Kuroiwa K,
    4. Naito S,
    5. Oda Y
    . The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol 2011;24:1272–80.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ishikawa K,
    2. Tsunekawa S,
    3. Ikeniwa M,
    4. Izumoto T,
    5. Iida A,
    6. Ogata H,
    7. et al.
    Long-term pancreatic beta cell exposure to high levels of glucose but not palmitate induces DNA methylation within the insulin gene promoter and represses transcriptional activity. PLoS One 2015;10:e0115350.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Chen M,
    2. Huang YL,
    3. Huang YC,
    4. Shui IM,
    5. Giovannucci E,
    6. Chen YC,
    7. et al.
    Genetic polymorphisms of the glycine N-methyltransferase and prostate cancer risk in the health professionals follow-up study. PLoS One 2014;9:e94683.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Huang YC,
    2. Lee CM,
    3. Chen M,
    4. Chung MY,
    5. Chang YH,
    6. Huang WJ,
    7. et al.
    Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 2007;13:1412–20.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Florez JC
    . It's not black and white: individualizing metformin treatment in type 2 diabetes. J Clin Endocrinol Metab 2014;99:3125–8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Foretz M,
    2. Guigas B,
    3. Bertrand L,
    4. Pollak M,
    5. Viollet B
    . Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953–66.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Albanes D,
    2. Weinstein SJ,
    3. Wright ME,
    4. Männistö S,
    5. Limburg PJ,
    6. Snyder K,
    7. et al.
    Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009;101:1272–9.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Wallace DC,
    2. Chalkia D
    . Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harb Perspect Biol 2013;5:a021220.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Wallace DC
    . Mitochondria and cancer. Nat Rev Cancer 2012;12:685–98.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Prevention Research: 9 (10)
October 2016
Volume 9, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
Citation Tools
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity
Edward Uchio, Frank L. Meyskens and Ping H. Wang
Cancer Prev Res October 1 2016 (9) (10) 777-778; DOI: 10.1158/1940-6207.CAPR-16-0173

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity
Edward Uchio, Frank L. Meyskens and Ping H. Wang
Cancer Prev Res October 1 2016 (9) (10) 777-778; DOI: 10.1158/1940-6207.CAPR-16-0173
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Clinical Challenges in Breast Cancer Prevention
  • Accelerating Cancer Prevention
  • MC1R and Precision Risk Assessment of Melanoma
Show more Commentaries
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement